(1S,3S)-3-氨基环己烷羧酸 | 933445-54-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (1S,3S)-3-氨基环己烷羧酸
• 英文名称: (1S,3S)-3-Aminocyclohexanecarboxylic acid
• 英文别名: (1S,3S)-3-aminocyclohexane-1-carboxylic acid
• CAS: 933445-54-6
• 化学式: C₇H₁₃NO₂
• 分子量: 143.18
• InChiKey: CKTUXQBZPWBFDX-WDSKDSINSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  67.8
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Inhibitors of protein kinases
  申请人：Zeitlmann Lutz

  公开号：US20110224225A1

  公开（公告）日：2011-09-15

  Compounds of general Formula (I): wherein R 1 , R 2 , R 3 , R a , A, B and x are as defined herein are inhibitors of protein kinases in particular members of the cyclin-dependent kinase family and/or the glycogen synthase kinase 3 family and are useful in preventing and/or treating any type of pain, inflammatory disorders, cancer, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases, metabolic disorders, renal diseases, neurologic and neuropsychiatric diseases and neurodegenerative diseases.

  通用式(I)的化合物： 其中R1、R2、R3、Ra、A、B和x的定义如本文所述，是特定于细胞周期蛋白激酶家族和/或糖原合成酶激酶3家族的抑制剂，并且在预防和/或治疗任何类型的疼痛、炎症性疾病、癌症、免疫性疾病、增殖性疾病、传染病、心血管疾病、代谢性疾病、肾脏疾病、神经和神经精神疾病以及神经退行性疾病方面具有用处。
• 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
  申请人：MSD Oss B.V.

  公开号：EP2548877A1

  公开（公告）日：2013-01-23

  The present invention provides 6-5 membered fused pyridine ring compounds according to Formula I or pharmaceutically acceptable salts thereof. or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.

  本发明提供了根据式I提供的6-5成员融合吡啶环化合物或其药学上可接受的盐。 或其药学上可接受的盐，或包含这些化合物的药物组合物以及它们在治疗中的使用。具体而言，本发明涉及在治疗布鲁顿氏酪氨酸激酶（Btk）介导的疾病中使用6-5成员融合吡啶环化合物。
• RHO KINASE INHIBITORS
  申请人：Bosanac Todd

  公开号：US20080161297A1

  公开（公告）日：2008-07-03

  Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.

  揭示了一种新颖的取代的2H-异喹啉-1-酮和3H-喹唑啉-4-酮衍生物，可用作Rho激酶的抑制剂，用于治疗通过Rho激酶活性介导或维持的各种疾病和疾病，包括心血管疾病，包含这些化合物的药物组合物，使用这些化合物的方法以及制备这些化合物的方法。
• METHODS FOR RENAL FUNCTION DETERMINATION
  申请人：MediBeacon Inc.

  公开号：US20190125902A1

  公开（公告）日：2019-05-02

  The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The method includes administering a pyrazine compound of Formula I to a patient and monitoring the rate in which the kidneys of the patient eliminate the pyrazine from the systemic circulation of the patient. The pyrazine compound fluoresces when exposed to electromagnetic radiation which is detected using one or more sensors. The rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.

  本公开涉及用于确定肾小球滤过率或评估患者肾功能的系统和方法。该方法包括向患者施用化合物I的吡嗪类化合物，并监测患者的肾脏从患者的全身循环中排除吡嗪的速率。当暴露于电磁辐射时，吡嗪化合物会发出荧光，使用一个或多个传感器来检测。患者体内荧光减少的速率被用来计算患者的肾小球滤过率。
• COMPOSITIONS AND SYSTEMS FOR RENAL FUNCTION DETERMINATION
  申请人：MediBeacon Inc.

  公开号：US20190125901A1

  公开（公告）日：2019-05-02

  The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The system includes a computing device, a power supply, one or more sensors, and at least one tracer agent that fluoresces when exposed to electromagnetic radiation. The electromagnetic radiation is detected using the sensors, and the rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.

  本公开涉及确定肾小球滤过率或评估需要的患者的肾功能的系统和方法。该系统包括计算设备、电源、一个或多个传感器，以及至少一种示踪剂，当暴露于电磁辐射时发出荧光。传感器检测电磁辐射，患者体内荧光减弱的速率用于计算患者的肾小球滤过率。